Literature DB >> 10463575

Common nonsense mutations in RAD52.

D W Bell1, D C Wahrer, D H Kang, M S MacMahon, M G FitzGerald, C Ishioka, K J Isselbacher, M Krainer, D A Haber.   

Abstract

RAD51, RAD52, and RAD54 encode proteins that are critical to the repair of double-strand DNA breaks by homologous recombination. The physical interactions among the products of RAD51, BRCA1, and BRCA2 have suggested that the BRCA1 and BRCA2 breast cancer susceptibility genes may function, at least in part, in this DNA damage repair pathway. Given the observation that different genes within a common functional pathway may be targeted by mutations in human cancers, we analyzed RAD51, RAD52, and RAD54 for the presence of germ-line mutations in 100 cases with early-onset breast cancer and for somatic mutations in 15 human breast cancer cell lines. Two premature stop codons, Ser346ter and Tyr415ter, were identified in germ-line RAD52 alleles from 5% of early-onset breast cancer cases. Together, these two heterozygous mutations were also found in 8% of a healthy control population, indicating that they do not confer an increased risk for breast cancer. A rare germ-line missense mutation was identified in RAD54, whereas no sequence variants were found in RAD51. None of the three RAD genes demonstrated somatic mutations in breast cancer cell lines. We conclude that, despite their potential functional association with the BRCA gene products, RAD51, RAD52, and RAD54 are not themselves targeted by mutations in human breast cancer. The presence of common nonsense mutations in RAD52 within the population may have significance for other conditions associated with potential alterations in DNA damage repair pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463575

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Coordinated response of mammalian Rad51 and Rad52 to DNA damage.

Authors:  Y Liu; N Maizels
Journal:  EMBO Rep       Date:  2000-07       Impact factor: 8.807

2.  RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.

Authors:  A K Siraj; M Al-Rasheed; M Ibrahim; K Siddiqui; F Al-Dayel; O Al-Sanea; S Uddin; K Al-Kuraya
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

3.  Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.

Authors:  Hong Wei Yang; Tae-Min Kim; Sydney S Song; Nihal Shrinath; Richard Park; Michel Kalamarides; Peter J Park; Peter M Black; Rona S Carroll; Mark D Johnson
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

4.  Functionally defective germline variants of sialic acid acetylesterase in autoimmunity.

Authors:  Ira Surolia; Stephan P Pirnie; Vasant Chellappa; Kendra N Taylor; Annaiah Cariappa; Jesse Moya; Haoyuan Liu; Daphne W Bell; David R Driscoll; Sven Diederichs; Khaleda Haider; Ilka Netravali; Sheila Le; Roberto Elia; Ethan Dow; Annette Lee; Jan Freudenberg; Philip L De Jager; Yves Chretien; Ajit Varki; Marcy E MacDonald; Tammy Gillis; Timothy W Behrens; Donald Bloch; Deborah Collier; Joshua Korzenik; Daniel K Podolsky; David Hafler; Mandakolathur Murali; Bruce Sands; John H Stone; Peter K Gregersen; Shiv Pillai
Journal:  Nature       Date:  2010-06-16       Impact factor: 49.962

5.  Variation in the RAD51 gene and familial breast cancer.

Authors:  Felicity Lose; Paul Lovelock; Georgia Chenevix-Trench; Graham J Mann; Gulietta M Pupo; Amanda B Spurdle
Journal:  Breast Cancer Res       Date:  2006-06-08       Impact factor: 6.466

6.  Overexpression of Rad51C splice variants in colorectal tumors.

Authors:  Arjun Kalvala; Li Gao; Brittany Aguila; Tyler Reese; Gregory A Otterson; Miguel A Villalona-Calero; Wenrui Duan
Journal:  Oncotarget       Date:  2015-04-20

7.  Hereditary breast cancer: ever more pieces to the polygenic puzzle.

Authors:  Natalia Bogdanova; Sonja Helbig; Thilo Dörk
Journal:  Hered Cancer Clin Pract       Date:  2013-09-11       Impact factor: 2.857

8.  Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma.

Authors:  Ping Li; YanZhen Xu; Qinle Zhang; Yu Li; Wenxian Jia; Xiao Wang; Zhibin Xie; Jiayi Liu; Dong Zhao; Mengnan Shao; Suixia Chen; Nanfang Mo; Zhiwen Jiang; Liuyan Li; Run Liu; Wanying Huang; Li Chang; Siyu Chen; Hongtao Li; Wenpu Zuo; Jiaquan Li; Ruoheng Zhang; Xiaoli Yang
Journal:  Cancer Cell Int       Date:  2019-11-06       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.